BIOGEN INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
BIOGEN INC. (BIIB) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $20.30 million as of 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2013-02-05
- 2012-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $20.30M.
- 2012-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $25.20M.
- 2012-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $25.40M.
- 2012-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $22.10M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2012-12-31 | $20.30M 10-K · filed 2013-02-05 |
| 2012-09-30 | $25.20M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $25.40M 10-Q · filed 2012-10-25 |
| 2012-03-31 | $22.10M 10-Q · filed 2012-07-24 |
| 2011-12-31 | $23.50M 10-K · filed 2013-02-05 |
| 2011-09-30 | $23.10M 10-Q · filed 2012-10-25 |
| 2011-06-30 | $20.60M 10-Q · filed 2012-10-25 |
| 2011-03-31 | $20.50M 10-Q · filed 2012-07-24 |
| 2010-12-31 | $20.80M 10-K · filed 2013-02-05 |
| 2010-09-30 | $21.80M 10-Q · filed 2011-10-28 |
| 2010-06-30 | $20.40M 10-Q · filed 2011-10-28 |
| 2010-03-31 | $20.80M 10-Q · filed 2011-07-26 |
| 2009-12-31 | $21.90M 10-K · filed 2012-02-03 |
| 2009-09-30 | $23.10M 10-Q · filed 2010-10-26 |
| 2009-06-30 | $21.60M 10-Q · filed 2010-10-26 |
| 2009-03-31 | $24.30M 10-Q · filed 2010-07-20 |
| 2008-12-31 | $23.90M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |